Biogen Asks Judge To Toss Neurological Drug Antitrust Suit
Law360, New York (May 25, 2017, 1:48 PM EDT) -- Biogen Inc. asked a California federal judge to toss an antitrust suit brought by a pharmaceutical research company, arguing Wednesday that the company failed to show how Biogen’s decision to enter a patent settlement and license agreement caused any harm to competition.
In a motion to dismiss with prejudice, Biogen argued that its settlement and license agreement with Forward Pharma FA ApS, which resulted in Forward’s termination of a collaboration agreement with Ixchel Pharma LLC, had no effect on competition in the market for dimethyl fumerate, the active ingredient in Biogen’s multiple sclerosis drug. Ixchel had alleged that Biogen specifically stopped a...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!